Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
1.201
-0.039 (-3.16%)
Jul 15, 2026, 11:35 AM EDT - Market open
Immuron Employees
Immuron had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$712,477
Profits / Employee
-$442,735
Market Cap
9.75M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 1 | 16.67% |
| Jun 30, 2023 | 6 | 1 | 20.00% |
| Jun 30, 2022 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 41 |
| Curis | 24 |
| BioCardia | 21 |
| Imunon | 20 |
| Theriva Biologics | 16 |
| BioRestorative Therapies | 14 |
| Kiora Pharmaceuticals | 13 |
| Aprea Therapeutics | 8 |
IMRN News
- 9 days ago - Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy - GlobeNewsWire
- 3 months ago - Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00 - Accesswire
- 3 months ago - Immuron Double Digit 3Q Sales Growth - GlobeNewsWire
- 4 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Accesswire
- 4 months ago - Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Benzinga
- 6 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - Accesswire
- 6 months ago - Immuron Reports Continued Sales Growth - GlobeNewsWire
- 7 months ago - Why Is Immuron Stock (IMRN) Down Today? - TipRanks